{"groups":[{"description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 milligrams per meter squared (mg/m\\^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.\n\nCisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray \\[Gy\\] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles","id":"FG000","title":"Arm A: Pemetrexed + Cisplatin and TRT"},{"description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22","id":"FG001","title":"Arm B: Etoposide + Cisplatin and TRT"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"124"},{"groupId":"FG001","numSubjects":"117"}],"type":"Participants censored (no death events)"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"301"},{"groupId":"FG001","numSubjects":"297"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"283"},{"groupId":"FG001","numSubjects":"272"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"229"},{"groupId":"FG001","numSubjects":"202"}],"type":"Entered Consolidation Phase"},{"achievements":[{"comment":"Study completion includes death due to any cause","groupId":"FG000","numSubjects":"177"},{"comment":"Study completion includes death due to any cause.","groupId":"FG001","numSubjects":"180"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"124"},{"groupId":"FG001","numSubjects":"117"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}